Status:
TERMINATED
Growth Hormone's Effect on the Cardiovascular System
Lead Sponsor:
Vanderbilt University
Collaborating Sponsors:
Pfizer
National Center for Research Resources (NCRR)
Conditions:
Growth Hormone Deficiency
Eligibility:
All Genders
18-65 years
Brief Summary
To evaluate specific markers of cardiovascular risk before and after growth hormone replacement therapy in a population of growth hormone deficient adults, as compared to an age, gender, and BMI-match...
Detailed Description
Growth hormone deficiency (GHD) is associated with increased cardiovascular morbidity and mortality. The effects of such a deficiency include decreased exercise capacity and tolerance, impaired cardia...
Eligibility Criteria
Inclusion
- Adult between the ages of 18 and 65
- Documented Growth Hormone Deficiency as defined by a peak Growth Hormone during a GHRH-Arginine Stimulation test not exceeding 9.5 ng/ml
Exclusion
- Personal history of cardiovascular disease (previous myocardial infarction or known coronary artery disease) or diagnosis of heart disease between study visits.
- Personal history of diabetes mellitus or development of diabetes between study visits.
- Initiation of an anti-cholesterol medication or anti-hypertensive between baseline and follow-up study visit.
- Initiation of regular tobacco use between baseline and follow-up study visit.
- Pregnancy or nursing
- Current daily use of any drug known to affect the fibrinolytic system: Aspirin, Aggrenox, Plavix, Persantine, Ticlid, Pletal, Trental, Lovenox, Coumadin, Agrylin, and Hydroxyurea.
Key Trial Info
Start Date :
August 1 2005
Trial Type :
OBSERVATIONAL
End Date :
December 1 2006
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00397319
Start Date
August 1 2005
End Date
December 1 2006
Last Update
July 3 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232